In summary, we demonstrated that IFN-β produced greater biological functions than IFN-α in mesothelioma, activated the p53 pathways and enhanced the anti-tumor effects of the first-line chemotherapeutic agents. This evidence concerns the gene IFNB1 and mesothelioma.